NCT02892019 - Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

June 19, 2019

Study Completion Date

July 17, 2019

Conditions

Asthma

Interventions

DRUG

Indacaterol acetate 75 μg

Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler

DRUG

Indacaterol acetate 150 μg

Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler

Trial Locations (29)

1000

Novartis Investigative Site, Manila

1008

Novartis Investigative Site, Manila

1020

Novartis Investigative Site, Brussels

1050

Novartis Investigative Site, Middelburg

1083

Novartis Investigative Site, Budapest

1113

Novartis Investigative Site, Quezon City

2045

Novartis Investigative Site, Törökbálint

6720

Novartis Investigative Site, Szeged

7500

Novartis Investigative Site, Panorama

7531

Novartis Investigative Site, Cape Town

7700

Novartis Investigative Site, Cape Town

7900

Novartis Investigative Site, Szigetvár

8000

Novartis Investigative Site, Bruges

10000

Novartis Investigative Site, Zagreb

35000

Novartis Investigative Site, Slavonski Brod

68161

Novartis Investigative Site, Mannheim

83026

Novartis Investigative Site, Rosenheim

94001

Novartis Investigative Site, Nové Zámky

196240

Novartis Investigative Site, Saint Petersburg

199106

Novartis Investigative Site, Saint Petersburg

Unknown

Novartis Investigative Site, Bogotá

Novartis Investigative Site, Bucaramanga

D 59063

Novartis Investigative Site, Hamm

01010

Novartis Investigative Site, Guatemala City

01011

Novartis Investigative Site, Guatemala City

01015

Novartis Investigative Site, Guatemala City

949 01

Novartis Investigative Site, Nitra

01330

Novartis Investigative Site, Adana

06100

Novartis Investigative Site, Ankara